Li H - Search Results

1

Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality.

Vader DT, Parikh RB, Li H, Imai K, Hubbard RA, Mamtani R. Vader DT, et al. Among authors: li h. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac050. doi: 10.1093/jncics/pkac050. JNCI Cancer Spectr. 2022. PMID: 35809072 Free PMC article.

2

Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.

Srivastava T, Prabhu VS, Li H, Xu R, Zarabi N, Zhong Y, Pellissier JM, Perini RF, de Wit R, Mamtani R. Srivastava T, et al. Among authors: li h. Eur Urol Oncol. 2020 Oct;3(5):663-670. doi: 10.1016/j.euo.2018.09.012. Epub 2018 Nov 22. Eur Urol Oncol. 2020. PMID: 31412001 Free article.

3

Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.

Patterson K, Prabhu V, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batteson R, Pellissier J, Keefe S, Grivas P, de Wit R. Patterson K, et al. Among authors: li h. Eur Urol Oncol. 2019 Sep;2(5):565-571. doi: 10.1016/j.euo.2018.09.009. Epub 2018 Nov 8. Eur Urol Oncol. 2019. PMID: 31412011 Free article.

4

The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.

Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Moreno BH, Godwin JL, Frenkl T, Sonpavde GP, Mamtani R. Slater RL, et al. Among authors: li h. J Med Econ. 2020 Sep;23(9):967-977. doi: 10.1080/13696998.2020.1770261. Epub 2020 Jun 12. J Med Econ. 2020. PMID: 32412387 Free article.

5

Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.

Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R. Hale O, et al. Among authors: li h. Clin Genitourin Cancer. 2021 Feb;19(1):e17-e30. doi: 10.1016/j.clgc.2020.07.006. Epub 2020 Jul 16. Clin Genitourin Cancer. 2021. PMID: 32826180 Free article.

6

Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer.

Mamtani R, Zhang H, Parikh RB, Patel K, Li H, Imai K, Hubbard RA. Mamtani R, et al. Among authors: li h. JAMA Netw Open. 2023 Apr 3;6(4):e238395. doi: 10.1001/jamanetworkopen.2023.8395. JAMA Netw Open. 2023. PMID: 37058309 Free PMC article.

7

Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma.

Doshi GK, Li H, Burcu M, Annavarapu S, Wells K, Imai K, Moreno BH, Singhal P, Mamtani R. Doshi GK, et al. Among authors: li h. Front Oncol. 2023 Oct 2;13:1210208. doi: 10.3389/fonc.2023.1210208. eCollection 2023. Front Oncol. 2023. PMID: 37849801 Free PMC article.

8

Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.

Narayan VM, Siolas D, Meadows ES, Turzhitsky V, Sillah A, Imai K, McMurry AJ, Li H. Narayan VM, et al. Among authors: li h. JCO Clin Cancer Inform. 2023 Sep;7:e2300096. doi: 10.1200/CCI.23.00096. JCO Clin Cancer Inform. 2023. PMID: 37906722 Free PMC article.

9

Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.

Freshwater T, Li H, Valiathan C, Li M, Perini R, Bracco OL, Frenkl T, Keefe S. Freshwater T, et al. Among authors: li h, li m. Am J Clin Oncol. 2019 Oct;42(10):802-809. doi: 10.1097/COC.0000000000000585. Am J Clin Oncol. 2019. PMID: 31503064

10

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.

Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Among authors: li h. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112,478 results

Search Page